Patient dosing has begun in a phase 1 trial evaluating QXL138AM, a masked immunocytokine targeting CD138, in advanced solid ...
High rates of overall response and MRD negativity were seen regardless of the dose patients received, said Andrew Spencer, MBBS.
In the end, all I could say is I have been there through sickness and your darkest times, and he didn’t say anything. I told ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback